Year in Review: Acute Lymphoblastic Leukemia — New ways to use CAR T-cell therapy and treatment de-intensification strategies by Mike Bassett , Staff Writer, MedPage Today December 5, 2022 ...

Source Reference: Gupta S, et al "Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children" N Engl J Med 2024; DOI: 10.1056/NEJMoa2411680.

Chemotherapy-free regimens in Philadelphia chromosome–positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...

Cycle Pharma enters exclusive US commercialization agreement with Handa for Phyrago to treat two types of leukaemia, Ph+ CML & Ph+ ALL: Cambridge, UK Wednesday, July 23, 2025, 16: ...

Highlights in acute lymphoblastic leukemia from ASH 2021 include pediatric regimens for adults, CNS involvement, and a possible transplant-sparing regimen, as reported by Dr Mark Litzow.

Current established regimens in adult acute lymphoblastic leukemia (ALL) result in a long-term overall survival (OS) rate of 40% to 50%. 1-4 Over the years, improvement in OS has been attributed to ...

The assessment of treatment response via the measurement of minimal residual disease (MRD) is now recognized as the most powerful prognostic factor in acute lymphoblastic leukemia (ALL). 1-4 The ...